{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:38Z","timestamp":1791229658699,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Correlations between dopamine transporter (DAT) availability and Parkinson\u2019s disease (PD) motor symptoms vary depending on the imaging modality, choice of regions of interest and clinical measures. We aimed to validate the PET radioligand [<jats:sup>18<\/jats:sup>F]FE-PE2I as a clinical biomarker in PD, hypothesizing negative correlations between DAT availability in specified nigrostriatal regions with symptom duration, disease stage and motor symptom scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 41 PD patients (age 45\u201379\u00a0years; H&amp;Y stage\u2009&lt;\u20093) and 37 healthy control subjects in a cross-sectional study with dynamic [<jats:sup>18<\/jats:sup>F]FE-PE2I PET. Binding potential (BP<jats:sub>ND<\/jats:sub>) was estimated in the caudate\u00a0nucleus, putamen, ventral striatum, sensorimotor striatum, and substantia nigra using the cerebellum as reference region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found negative correlations (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02) between symptom duration and BP<jats:sub>ND<\/jats:sub> in the putamen and sensorimotor striatum (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>\u2009=\u2009\u2212\u2009.42; <jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>\u2009=\u2009\u2212\u2009.51), and between H&amp;Y stage and BP<jats:sub>ND<\/jats:sub> in caudate\u00a0nucleus, putamen, sensorimotor striatum, and substantia nigra (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub> between \u2212\u00a0.40 and \u2212\u00a0.54). The first correlations were better described with exponential fitting. MDS-UPDRS-III in \u2018OFF\u2019 state correlated negatively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.04) with BP<jats:sub>ND<\/jats:sub> in the sensorimotor striatum (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>\u2009=\u2009\u2212\u2009.47), and excluding tremor score also in the putamen (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>\u2009=\u2009\u2212\u2009.45).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Results are in agreement with earlier findings in in vivo and post-mortem studies and validate [<jats:sup>18<\/jats:sup>F]FE-PE2I as a functional PD biomarker for PD severity.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: EudraCT 2011-0020050, Registered April 26 2011; EudraCT 2017-003327-29, Registered October 08 2017; EudraCT 2017-001585-19, Registered August 2 2017. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/eudract.ema.europa.eu\/\">https:\/\/eudract.ema.europa.eu\/<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-023-00974-7","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T11:02:59Z","timestamp":1680692579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["[18F]FE-PE2I DAT correlates with Parkinson\u2019s disease duration, stage, and rigidity\/bradykinesia scores: a PET radioligand validation study"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5770-8419","authenticated-orcid":false,"given":"Vera S.","family":"Kerstens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Sundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Halldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Varrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"974_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet (London, England). 2015;386(9996):896\u2013912.","journal-title":"Lancet (London, England)"},{"issue":"22","key":"974_CR2","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1212\/01.wnl.0000335973.66333.58","volume":"71","author":"R Nandhagopal","year":"2008","unstructured":"Nandhagopal R, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study. Neurology. 2008;71(22):1790\u20135.\u00a0","journal-title":"Neurology"},{"issue":"1","key":"974_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mds.27183","volume":"33","author":"W Li","year":"2018","unstructured":"Li W, et al. 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson\u2019s: a longitudinal study. Mov Disord. 2018;33(1):117\u201327.\u00a0","journal-title":"Mov Disord"},{"key":"974_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V","volume":"15","author":"HTS Benamer","year":"2000","unstructured":"Benamer HTS, et al. Correlation of Parkinson\u2019s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692-8.","journal-title":"Mov Disord"},{"issue":"2","key":"974_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s00259-005-1904-y","volume":"33","author":"SA Eshuis","year":"2006","unstructured":"Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging. 2006;33(2):200-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"974_CR6","unstructured":"Ishikawa T, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-\u03b2CIT-FP\/SPECT and fluorine-18-FDOPA\/PET. J Nucl Med. 1996 Nov;37(11):1760\u20135."},{"key":"974_CR7","unstructured":"Shih MC, et al. Neuroimaging of the dopamine transporter in Parkinson\u2019s disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil. Arq Neuropsiquiatr. 2006;64(3A):628\u201334."},{"issue":"6","key":"974_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10072-006-0718-4","volume":"27","author":"S Ottaviani","year":"2006","unstructured":"Ottaviani S, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson\u2019s disease. Neurol Sci. 2006;27(6):397-401.\u00a0","journal-title":"Neurol Sci"},{"key":"974_CR9","doi-asserted-by":"crossref","unstructured":"Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it? Mov Disord. 2003;18 Suppl 7:S43\u201351.","DOI":"10.1002\/mds.10579"},{"key":"974_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410380407","volume":"38","author":"JP Seibyl","year":"1995","unstructured":"Seibyl JP, et al. Decreased single-photon emission computed tomographic {123I}\u03b2-CIT striatal uptake correlates with symptom severity in parkinson\u2019s disease. Ann Neurol. 1995;38(4):589\u201398.","journal-title":"Ann Neurol"},{"issue":"6","key":"974_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/mds.1256","volume":"16","author":"A Varrone","year":"2001","unstructured":"Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [123I]\u03b2-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2001;16(6):1023\u201332.","journal-title":"Mov Disord"},{"issue":"6","key":"974_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.25103","volume":"82","author":"V Kaasinen","year":"2017","unstructured":"Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. Ann Neurol. 2017;82(6):873\u201382.","journal-title":"Ann Neurol"},{"key":"974_CR13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.neuroimage.2007.12.063","volume":"40","author":"S Cervenka","year":"2008","unstructured":"Cervenka S, B\u00e4ckman L, Csel\u00e9nyi Z, Halldin C, Farde L. Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. Neuroimage. 2008;40(3):1287\u201395.","journal-title":"Neuroimage"},{"issue":"1","key":"974_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.neuroimage.2010.06.044","volume":"54","author":"AC Tziortzi","year":"2011","unstructured":"Tziortzi AC, et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage. 2011;54(1):264-77.","journal-title":"Neuroimage"},{"key":"974_CR15","doi-asserted-by":"crossref","unstructured":"Kerstens VS, et al. Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson\u2019s disease. EJNMMI Res. 2020;10(1):95.","DOI":"10.1186\/s13550-020-00676-4"},{"key":"974_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2967\/jnumed.111.101626","volume":"53","author":"T Sasaki","year":"2012","unstructured":"Sasaki T, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. 2012;53(7):1065\u201373.","journal-title":"J Nucl Med"},{"key":"974_CR17","doi-asserted-by":"publisher","unstructured":"Suzuki M, et al. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[\u03b2-11C]DOPA and [18F]FE-PE2I in humans. Nucl Med Commun Wolters Kluwer Heal Nucl Med Commun. 2014;35(3):231-7. https:\/\/doi.org\/10.1097\/MNM.0000000000000052.","DOI":"10.1097\/MNM.0000000000000052"},{"key":"974_CR18","doi-asserted-by":"crossref","unstructured":"Varrone A, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63(10):871\u201380.","DOI":"10.1002\/syn.20670"},{"issue":"1","key":"974_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2967\/jnumed.110.077651","volume":"52","author":"A Varrone","year":"2011","unstructured":"Varrone A, et al. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med. 2011;52(1):132\u20139.","journal-title":"J Nucl Med"},{"key":"974_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/brain\/awz120","volume":"142","author":"A Mart\u00edn-Bastida","year":"2019","unstructured":"Mart\u00edn-Bastida A, et al. Relationship between neuromelanin and dopamine terminals within the Parkinson\u2019s nigrostriatal system. Brain. 2019;142(7):2023\u201336.","journal-title":"Brain"},{"key":"974_CR21","doi-asserted-by":"crossref","unstructured":"Fazio P, et al. Nigrostriatal dopamine transporter availability in early Parkinson\u2019s disease. Mov Disord. 2018;33(4):592\u20139.","DOI":"10.1002\/mds.27316"},{"issue":"6","key":"974_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jlcr.2927","volume":"55","author":"V Stepanov","year":"2012","unstructured":"Stepanov V, et al. An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters. J Label Compd Radiopharm. 2012;55(6):206\u201310.","journal-title":"J Label Compd Radiopharm"},{"key":"974_CR23","doi-asserted-by":"crossref","unstructured":"Varrone A, Sj\u00f6holm N, Eriksson L, Guly\u00e1s B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36(10):1639\u201350.","DOI":"10.1007\/s00259-009-1156-3"},{"key":"974_CR24","doi-asserted-by":"publisher","unstructured":"Derringer, J. A simple correction for non-independent tests. 2018. https:\/\/doi.org\/10.31234\/OSF.IO\/F2TYW.","DOI":"10.31234\/OSF.IO\/F2TYW"},{"issue":"3","key":"974_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.hdy.6800717","volume":"95","author":"J Li","year":"2005","unstructured":"Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95(3):221\u20137.","journal-title":"Heredity"},{"issue":"5","key":"974_CR26","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing and parkinson\u2019s disease: Substantia nigra regional selectivity. Brain. 1991;114(5):2283-301.","journal-title":"Brain"},{"key":"974_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.26907","volume":"32","author":"AP Strafella","year":"2017","unstructured":"Strafella AP, et al. Molecular imaging to track Parkinson\u2019s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord. 2017;32(2):181\u201392.","journal-title":"Mov Disord"},{"key":"974_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2014.290","volume":"71","author":"IT Hsiao","year":"2014","unstructured":"Hsiao IT, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71(6):758\u201366.","journal-title":"JAMA Neurol"},{"issue":"4","key":"974_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archneur.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard S, et al. Motor score of the unified Parkinson disease rating scale as a good predictor of lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006;63(4):584\u20138.","journal-title":"Arch Neurol"},{"issue":"6","key":"974_CR30","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1212\/WNL.48.6.1578","volume":"48","author":"M Guttman","year":"1997","unstructured":"Guttman M, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa- naive Parkinson\u2019s disease: Implications for the symptomatic threshold. Neurology. 1997;48(6):1578-83.","journal-title":"Neurology"},{"issue":"1","key":"974_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0022-510X(97)00100-7","volume":"151","author":"SY Ma","year":"1997","unstructured":"Ma SY, R\u00f6ytt\u00e4 M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson\u2019s disease using disector counts. J Neurol Sci. 1997;151(1):83-7.","journal-title":"J Neurol Sci"},{"issue":"2","key":"974_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.expneurol.2012.07.008","volume":"237","author":"SD Tabbal","year":"2012","unstructured":"Tabbal SD, et al. Low nigrostriatal reserve for motor Parkinsonism in nonhuman primates. Exp Neurol. 2012;237(2):355-62.","journal-title":"Exp Neurol"},{"key":"974_CR33","doi-asserted-by":"crossref","unstructured":"Jakobson Mo, S. et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT\u2014a clinical comparison. EJNMMI Res. 2018;8(1):100.","DOI":"10.1186\/s13550-018-0450-0"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-023-00974-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-023-00974-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-023-00974-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T11:06:55Z","timestamp":1680692815000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-023-00974-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1186\/s13550-023-00974-7","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority, the Radiation Safety Committee of the Karolinska University Hospital, and the Swedish Medicinal Product Agency (EudraCT 2011-0020050, EudraCT 2017-003327-29, and 2017-001585-19). Patients provided written informed consent for study participation. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"At the time of writing of the manuscript, Andrea Varrone is employed at H. Lundbeck A\/S. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}